Start the conversation
When we recommended Celldex Therapeutics Inc. (Nasdaq: CLDX) to you in the April 2012 special research report "The Biotech Buyout Binge," shares of the Needham, Mass.-based oncology firm were trading at $5.19 a share.
Yesterday, Celldex shares hit a new 52-week high of $34.24 - representing a 560% gain in just 17 months.
And Leerink Swann analyst Howard Liang on Monday lifted his Celldex target price from $29 to $45 - which is 767% above where we recommended the stock to you.
This is premium content for Private Briefing subscribers only.